Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea

Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea

Background/Aims: Sorafenib is the standard of care in the management of advanced hepatocellular carcinoma (HCC). The purpose of this study was to investigate the characteristics, treatment patterns and outcomes of sorafenib among HCC patients in South Korea.Methods: This population-based retrospecti...

Full description

Bibliographic Details
Main Authors: Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park
Format: Article
Language:English
Published: Gastroenterology Council for Gut and Liver 2024-01-01
Series:Gut and Liver
Subjects:
carcinoma
hepatocellular
sorafenib
survival
Online Access:http://gutnliver.org/journal/view.html?doi=10.5009/gnl220406

Internet

http://gutnliver.org/journal/view.html?doi=10.5009/gnl220406

Similar Items